These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 29136445)

  • 1. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.
    Sampson HA; Shreffler WG; Yang WH; Sussman GL; Brown-Whitehorn TF; Nadeau KC; Cheema AS; Leonard SA; Pongracic JA; Sauvage-Delebarre C; Assa'ad AH; de Blay F; Bird JA; Tilles SA; Boralevi F; Bourrier T; Hébert J; Green TD; Gerth van Wijk R; Knulst AC; Kanny G; Schneider LC; Kowalski ML; Dupont C
    JAMA; 2017 Nov; 318(18):1798-1809. PubMed ID: 29136445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
    Fleischer DM; Greenhawt M; Sussman G; Bégin P; Nowak-Wegrzyn A; Petroni D; Beyer K; Brown-Whitehorn T; Hebert J; Hourihane JO; Campbell DE; Leonard S; Chinthrajah RS; Pongracic JA; Jones SM; Lange L; Chong H; Green TD; Wood R; Cheema A; Prescott SL; Smith P; Yang W; Chan ES; Byrne A; Assa'ad A; Bird JA; Kim EH; Schneider L; Davis CM; Lanser BJ; Lambert R; Shreffler W
    JAMA; 2019 Mar; 321(10):946-955. PubMed ID: 30794314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.
    Fleischer DM; Shreffler WG; Campbell DE; Green TD; Anvari S; Assa'ad A; Bégin P; Beyer K; Bird JA; Brown-Whitehorn T; Byrne A; Chan ES; Cheema A; Chinthrajah S; Chong HJ; Davis CM; Ford LS; Gagnon R; Greenhawt M; Hourihane JO; Jones SM; Kim EH; Lange L; Lanser BJ; Leonard S; Mahler V; Maronna A; Nowak-Wegrzyn A; Oriel RC; O'Sullivan M; Petroni D; Pongracic JA; Prescott SL; Schneider LC; Smith P; Staab D; Sussman G; Wood R; Yang WH; Lambert R; Peillon A; Bois T; Sampson HA
    J Allergy Clin Immunol; 2020 Oct; 146(4):863-874. PubMed ID: 32659313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AR101 Oral Immunotherapy for Peanut Allergy.
    ; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
    N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
    Greenhawt M; Sindher SB; Wang J; O'Sullivan M; du Toit G; Kim EH; Albright D; Anvari S; Arends N; Arkwright PD; Bégin P; Blumchen K; Bourrier T; Brown-Whitehorn T; Cassell H; Chan ES; Ciaccio CE; Deschildre A; Divaret-Chauveau A; Dorris SL; Dorsey MJ; Eiwegger T; Erlewyn-Lajeunesse M; Fleischer DM; Ford LS; Garcia-Lloret M; Giovannini-Chami L; Hourihane JO; Jay N; Jones SM; Kerns LA; Kloepfer KM; Leonard S; Lezmi G; Lieberman JA; Lomas J; Makhija M; Parrish C; Peake J; Perrett KP; Petroni D; Pfützner W; Pongracic JA; Quinn P; Robison RG; Sanders G; Schneider L; Sharma HP; Trujillo J; Turner PJ; Tuttle K; Upton JE; Varshney P; Vickery BP; Vogelberg C; Wainstein B; Wood RA; Bee KJ; Campbell DE; Green TD; Rouissi R; Peillon A; Bahnson HT; Bois T; Sampson HA; Burks AW
    N Engl J Med; 2023 May; 388(19):1755-1766. PubMed ID: 37163622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy.
    Remington BC; Krone T; Kim EH; Bird JA; Green TD; Lack G; Fleischer DM; Koppelman SJ
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):488-493.e2. PubMed ID: 31442495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.
    Michaud E; Evrard B; Pereira B; Rochette E; Bernard L; Rouzaire PO; Gourdon-Dubois N; Merlin E; Fauquert JL
    Trials; 2015 Apr; 16():197. PubMed ID: 25925398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.
    Jones SM; Sicherer SH; Burks AW; Leung DY; Lindblad RW; Dawson P; Henning AK; Berin MC; Chiang D; Vickery BP; Pesek RD; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA;
    J Allergy Clin Immunol; 2017 Apr; 139(4):1242-1252.e9. PubMed ID: 28091362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy.
    Fleischer DM; Spergel JM; Kim EH; Campbell DE; Green TD; Bee KJ; Lambert R; Ocheltree T; Sampson HA
    Allergy Asthma Proc; 2020 Jul; 41(4):278-284. PubMed ID: 32517847
    [No Abstract]   [Full Text] [Related]  

  • 12. An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial.
    Fleischer DM; Chinthrajah S; Scurlock AM; Campbell DE; Green TD; Bee KJ; Peillon A; Ocheltree T; Sampson HA
    Allergy Asthma Proc; 2020 Sep; 41(5):326-335. PubMed ID: 32539908
    [No Abstract]   [Full Text] [Related]  

  • 13. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.
    Pongracic JA; Gagnon R; Sussman G; Siri D; Oriel RC; Brown-Whitehorn TF; Green TD; Campbell DE; Anvari S; Berger WE; Bird JA; Chan ES; Cheema A; Chinthrajah RS; Chong HJ; Dowling PJ; Fineman SM; Fleischer DM; Gonzalez-Reyes E; Kim EH; Lanser BJ; MacGinnitie A; Mehta H; Petroni D; Rupp N; Schneider LC; Scurlock AM; Sher LD; Shreffler WG; Sindher SB; Stillerman A; Wood R; Yang WH; Bois T; Sampson HA; Bégin P
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1864-1873.e10. PubMed ID: 34848381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow's Milk Allergy: A Randomized Clinical Trial.
    Petroni D; Bégin P; Bird JA; Brown-Whitehorn T; Chong HJ; Fleischer DM; Gagnon R; Jones SM; Leonard S; Makhija MM; Oriel RC; Shreffler WG; Sindher SB; Sussman GL; Yang WH; Bee KJ; Bois T; Campbell DE; Green TD; Rutault K; Sampson HA; Wood RA
    JAMA Pediatr; 2024 Apr; 178(4):345-353. PubMed ID: 38407859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
    Dupont C; Burks AW; Fleischer DM; Bee KJ; Chainani S; Sampson HA
    Expert Rev Clin Immunol; 2024 Jun; 20(6):623-633. PubMed ID: 38323337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
    DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
    Blumchen K; Trendelenburg V; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Roeder M; Rosenfeld L; Hartmann O; Niggemann B; Beyer K
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):479-491.e10. PubMed ID: 30423449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.